228 patents
Page 9 of 12
Utility
Methods for therapeutic administration of messenger ribonucleic acid drugs
30 Nov 20
The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject.
Stephen Hoge, Tirtha Chakraborty, Gilles Besin, Ruchi Jain
Filed: 4 Oct 16
Utility
Nucleic Acid-Based Therapy of Muscular Dystrophies
25 Nov 20
The invention related to polynucleotides comprising an open reading frame of linked nucleosides encoding therapeutic proteins or variant therapeutic proteins, isoforms thereof, functional fragments thereof, and fusion proteins comprising therapeutic proteins.
Paolo Martini
Filed: 23 Feb 18
Utility
Chikv Rna Vaccines
25 Nov 20
Aspects of the disclosure relate to nucleic acid vaccines.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
Filed: 9 Jun 20
Utility
Zika Virus Mrna Vaccines
25 Nov 20
Aspects of the disclosure relate to nucleic acid vaccines.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu
Filed: 9 Jun 20
Utility
Polynucleotides Encoding Anti-chikungunya Virus Antibodies
25 Nov 20
This disclosure relates to compositions and methods for treating and preventing chikungunya virus infection by delivering polynucleotides encoding anti-chikungunya virus antibodies to a subject.
Sunny Himansu, James E. Crowe, Jr., Giuseppe Ciaramella
Filed: 3 Jan 19
Utility
USE OF MRNAS ENCODING OX40L, IL-23 AND IL-36gamma IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE FOR TREATING CANCER
18 Nov 20
The disclosure features methods for treating solid tumor malignancies and lymphomas by administering LNP encapsulated mRNAs encoding human OX40L, IL-23 and IL-36y polypeptides alone or in combination with checkpoint blockade.
Robert MEEHAN, Tal ZAKS
Filed: 7 Jan 20
Utility
Methods of Preparing Modified Rna
18 Nov 20
The present disclosure relates to methods for preparing a modified RNA comprising enzymatically ligating an acceptor moiety having a 3′-hydroxyl group to the 5′-end of a donor moiety (e.g., installation of 5′-triphosphate groups, mRNA caps, or cap-like structures on chemically synthesized RNA or installation of 5′-triphosphate groups, mRNA caps, cap-like structures, or non-cap like structures on enzymatically prepared RNA).
Kristen OTT, Aaron LARSEN, I-Ping CHAN, Jennifer NELSON, William ISSA, Melissa J. MOORE
Filed: 16 Aug 18
Utility
Polynucleotides Encoding Relaxin
11 Nov 20
The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.
Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 29 Jul 20
Utility
Modified Polynucleotides for the Production of Secreted Proteins
11 Nov 20
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
Antonin DE FOUGEROLLES, Justin GUILD
Filed: 1 Jul 20
Utility
Lipid Nanoparticles for Delivering Modified Rna Encoding a Vegf-a Polypeptide
28 Oct 20
The disclosure relates to nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide.
Kenny Mikael Hansson, Kerry Benenato, Maria Wågberg, Annika Pålsson, Regina Fritsche-Danielson
Filed: 30 Oct 18
Utility
Human Cytomegalovirus Vaccine
28 Oct 20
The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John
Filed: 30 Apr 20
Utility
Polynucleotides encoding immune modulating polypeptides
26 Oct 20
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding at least one polypeptide of interest to modulate the immune response.
Joseph Beene Bolen, Joshua P. Frederick
Filed: 14 Jun 18
Utility
Compounds and compositions for intracellular delivery of agents
12 Oct 20
The disclosure features amino lipids and compositions involving the same.
Kerry E. Benenato, William Butcher
Filed: 21 Dec 16
Utility
Lipid Nanoparticles
7 Oct 20
The invention features methods and apparatus for producing lipid nanoparticles.
Benjamin Frank GELDHOF
Filed: 20 Jun 17
Utility
Methods and Apparatus for Filtration
7 Oct 20
The invention features methods and apparatus for concentrating a nucleic acid.
Benjamin Frank GELDHOF
Filed: 20 Jun 17
Utility
Methods and Apparatus for Purifying Rna
30 Sep 20
The invention features methods and apparatus for purifying a sample including an RNA (e.g., an RNA having a poly(A) sequence, such as an mRNA).
Benjamin Frank GELDHOF
Filed: 20 Jun 17
Utility
Methods of Making Lipid Nanoparticles
30 Sep 20
The disclosure features novel methods of producing nucleic acid lipid nanoparticle (LNP) compositions employing a modifying agent after formation of a precursor nucleic acid lipid nanoparticle, the produced compositions thereof, and methods involving the nucleic acid lipid nanoparticles useful in the delivery of therapeutics and/or prophylactics, such as a nucleic acid, to mammalian cells or organs to, for example, to regulate polypeptide, protein, or gene expression.
Joseph SCHARITER, Kimberly HASSETT, Mike SMITH, Orn ALMARSSON, Luis BRITO
Filed: 30 Aug 18
Utility
Polynucleotides Encoding Ornithine Transcarbamylase for the Treatment of Urea Cycle Disorders
23 Sep 20
This disclosure relates mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC), isoforms thereof, functional fragments thereof, and fusion proteins comprising OTC. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.
Zhijian Zhuo, Andrea Lea Frassetto, Paolo G.V. Martini, Vladimir Presnyak, Patrick Finn
Filed: 20 Nov 18
Utility
Chikungunya Virus Rna Vaccines
16 Sep 20
The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof.
Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
Filed: 20 Apr 20
Utility
Zika Virus Rna Vaccines
16 Sep 20
The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof.
Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
Filed: 15 Apr 20